{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1130","value":"1020"},{"groupId":"OG001","spread":"651","value":"709"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"},{"description":"Participants were randomized to ibrutinib 560 mg and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG001","title":"Randomization Phase: Ibrutinib + Placebo"}],"paramType":"MEAN","populationDescription":"Participants with an evaluable PK assessment at given time point.","reportingStatus":"POSTED","timeFrame":"Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose","title":"Steady-State PK of Ibrutinib: Apparent Total Clearance at Steady State (CLss/F) (Randomization Phase)","type":"SECONDARY","unitOfMeasure":"L/hour"}